{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:12:37Z","timestamp":1778649157550,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acral melanoma represents a biologically distinct and clinically aggressive melanoma subtype disproportionately affecting non-Caucasian populations. Evidence from low- and middle-income countries remains limited, and the real-world impact of modern immunotherapy in these patients is not well characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe clinical characteristics, treatment patterns, and survival outcomes of patients with acral melanoma treated at a comprehensive cancer center in Latin America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study including adult patients with histologically confirmed acral melanoma involving the palms, soles, or nail apparatus. Sociodemographic, clinical, pathological, and treatment data were collected. Overall survival was estimated using the Kaplan\u2013Meier method and compared with the log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-seven patients with acral melanoma were included; 18 (38.3%) died during follow-up. Median age at diagnosis was 65.3 years, with less favorable survival observed among older patients. Estimated overall survival was 62.2% at 1 year and 59.4% at both 3 and 5 years. Females and patients aged \u226465 years showed higher survival estimates across follow-up. Immunotherapy was the most frequently used systemic treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Acral melanoma in this Latin American cohort showed unfavorable long-term survival, consistent with late-stage presentation and potential delays in detection, highlighting ongoing diagnostic and treatment shortfalls in middle-income settings. Real-world experience suggests that immunotherapy is being adopted in routine practice, while access to specialized care remains uneven. Multicenter regional studies are needed to better characterize outcomes and inform context-appropriate management strategies in underrepresented populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1828547","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:47:32Z","timestamp":1778647652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and real-world survival in acral melanoma: experience from a comprehensive cancer center in Latin America"],"prefix":"10.3389","volume":"16","author":[{"given":"Diego","family":"G\u00f3mez-Abreo","sequence":"first","affiliation":[{"name":"Department of Oncology, Hospital Internacional de Colombia (HIC), Fundaci\u00f3n Cardiovascular de Colombia (FCV)","place":["Floridablanca, Santander, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Steven Villabona","family":"D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hospital Internacional de Colombia (HIC), Fundaci\u00f3n Cardiovascular de Colombia (FCV)","place":["Floridablanca, Santander, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalia Andrea","family":"Olarte-Licht","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Hospital Internacional de Colombia (HIC), Fundaci\u00f3n Cardiovascular de Colombia (FCV)","place":["Floridablanca, Santander, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lady Katerine Aldana","family":"Galvis","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hospital Internacional de Colombia (HIC), Fundaci\u00f3n Cardiovascular de Colombia (FCV)","place":["Floridablanca, Santander, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan Danilo Torres","family":"Rosas","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hospital Internacional de Colombia (HIC), Fundaci\u00f3n Cardiovascular de Colombia (FCV)","place":["Floridablanca, Santander, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Hurtado-Ortiz","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Hospital Internacional de Colombia (HIC), Fundaci\u00f3n Cardiovascular de Colombia (FCV)","place":["Floridablanca, Santander, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maricel","family":"Licht-Ardila","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Hospital Internacional de Colombia (HIC), Fundaci\u00f3n Cardiovascular de Colombia (FCV)","place":["Floridablanca, Santander, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar Fabi\u00e1n","family":"Manrique-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Hospital Internacional de Colombia (HIC), Fundaci\u00f3n Cardiovascular de Colombia (FCV)","place":["Floridablanca, Santander, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-199609001-00026","article-title":"Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036","volume":"152","author":"Garbe","year":"2021","journal-title":"Eur J Cancer Oxford England: 1990"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: A Cancer J For Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12967-022-03532-2","article-title":"Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma","volume":"20","author":"Gui","year":"2022","journal-title":"J Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","article-title":"Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity","volume":"11","author":"Newell","year":"2020","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer J For Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10772.x","article-title":"Melanoma of the hand and foot: epidemiological, prognostic and genetic features. A systematic review","volume":"166","author":"Durbec","year":"2012","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3089-0","article-title":"Prognosis of acral melanoma: a series of 281 patients","volume":"20","author":"Bello","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70335-3","article-title":"Cancer survival in Africa, Asia, and Central America: a population-based study","volume":"11","author":"Sankaranarayanan","year":"2010","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61152-x","article-title":"Expansion of cancer care and control in countries of low and middle income: a call to action","volume":"376","author":"Farmer","year":"2010","journal-title":"Lancet Lond England"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.049","article-title":"Survival differences in acral lentiginous melanoma according to socioeconomic status and race","volume":"86","author":"Yan","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5394-x","article-title":"Melanoma in Mexico: clinicopathologic features in a population with predominance of acral lentiginous subtype","volume":"23","author":"Lino-Silva","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13913","article-title":"Survival of acral lentiginous melanoma in the National Cancer Institute of Colombia","volume":"31","author":"Duarte","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/srep31432","article-title":"Acral melanoma in Chinese: A clinicopathological and prognostic study of 142 cases","volume":"6","author":"Lv","year":"2016","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7196\/samj.2018.v108i9.13435","article-title":"Clinical and pathological features of acral melanoma in a South African population: A retrospective study","volume":"108","author":"De Wet","year":"2018","journal-title":"S Afr Med J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA\u00a0Cancer J Clin"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41379-022-01101-y","article-title":"Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies","volume":"35","author":"Sadurn\u00ed","year":"2022","journal-title":"Mod Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.15446\/rsap.v20n2.65616","article-title":"Epidemiological profile of primary cutaneous melanoma over a 15-year period at a private skin cancer center in Colombia","volume":"20","author":"Pozzobon","year":"2018","journal-title":"Rev Salud P\u00fablica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.5070\/D32210032913","article-title":"Delay in diagnosis of acral melanoma","volume":"22","author":"Rheingantz da Cunha Filho","year":"2016","journal-title":"Dermatol Online J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3100-9","article-title":"Age as a prognostic factor in patients with localized melanoma and regional metastases","volume":"20","author":"Balch","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12967-016-1026-2","article-title":"Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts","volume":"14","author":"Weiss","year":"2016","journal-title":"J Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71223","article-title":"Cellular senescence and immunosenescence in melanoma: Insights from the tumor microenvironment","volume":"14","author":"Xiong","year":"2025","journal-title":"Cancer Med"},{"key":"B26","unstructured":"Melanoma statistics 2025: complete global and canadian data analysis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.44.5031","article-title":"Sex is an independent prognostic indicator for survival and relapse\/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials","volume":"31","author":"Joosse","year":"2013","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.602705","article-title":"Immune checkpoint inhibitors in advanced acral melanoma: A systematic review","volume":"10","author":"Zheng","year":"2020","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-46029-1_15-1","article-title":"The\u00a0efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz429.003","article-title":"Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis","volume":"31","author":"Cho","year":"2021","journal-title":"Melanoma Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1828547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:47:42Z","timestamp":1778647662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1828547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1828547"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1828547","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1828547"}}